Selected article for: "alternative approach and urgent need"

Author: Wanve, Madhuri; Kaur, Harpreet; Sarmah, Deepaneeta; Saraf, Jackson; Pravalika, Kanta; Vats, Kanchan; Kalia, Kiran; Borah, Anupom; Yavagal, Dileep R.; Dave, Kunjan R.; Bhattacharya, Pallab
Title: Therapeutic spectrum of interferon‐β in ischemic stroke
  • Cord-id: rkb9z5t9
  • Document date: 2018_10_15
  • ID: rkb9z5t9
    Snippet: Ischemic stroke is devastating and a major cause of morbidity and mortality worldwide. To date, only clot retrieval devices and/or intravenous tissue plasminogen activators (tPA) have been approved by the US‐FDA for the treatment of acute ischemic stroke. Therefore, there is an urgent need to develop an effective treatment for stroke that can have limited shortcomings and broad spectrum of applications. Interferon‐beta (IFN‐β), an endogenous cytokine and a key anti‐inflammatory agent, c
    Document: Ischemic stroke is devastating and a major cause of morbidity and mortality worldwide. To date, only clot retrieval devices and/or intravenous tissue plasminogen activators (tPA) have been approved by the US‐FDA for the treatment of acute ischemic stroke. Therefore, there is an urgent need to develop an effective treatment for stroke that can have limited shortcomings and broad spectrum of applications. Interferon‐beta (IFN‐β), an endogenous cytokine and a key anti‐inflammatory agent, contributes toward obviating deleterious stroke outcomes. Therefore, exploring the role of IFN‐β may be a promising alternative approach for stroke intervention in the future. In the present review, we have discussed about IFN‐β along with its different mechanistic roles in ischemic stroke. Furthermore, therapeutic approaches targeting the inflammatory cascade with IFN‐β therapy that may be helpful in improving stroke outcome are also discussed.

    Search related documents:
    Co phrase search for related documents
    • activation induction and acute injury: 1
    • activation induction and acute phase: 1, 2
    • activation induction and adhesion molecule: 1
    • activation induction and adhesion molecule expression: 1
    • activation induction and lupus erythematosus: 1
    • activation induction and macrophage inflammatory: 1
    • activator signal transducer and acute injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • activator signal transducer and adhesion molecule: 1, 2, 3, 4
    • activator signal transducer and adhesion molecule expression: 1
    • activator signal transducer and adjuvant therapy: 1
    • activator signal transducer and lupus erythematosus: 1, 2
    • activator signal transducer and macrophage inflammatory: 1, 2
    • acute injury and adhesion molecule: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute injury and adhesion molecule expression: 1, 2
    • acute injury and adjuvant therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute injury and lupus erythematosus: 1, 2, 3, 4, 5
    • acute injury and macrophage inflammatory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute injury and macrophage monocyte: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute ischemic stroke and adhesion molecule: 1